PMID- 18393977
OWN - NLM
STAT- MEDLINE
DCOM- 20080708
LR  - 20190828
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 52
IP  - 6
DP  - 2008 May
TI  - Genetic alterations of CCND1 and EMSY in breast cancers.
PG  - 698-705
LID - 10.1111/j.1365-2559.2008.03007.x [doi]
AB  - AIMS: CCND1 and EMSY, on 11q13, are frequently amplified in breast cancer. CCND1 
      is implicated in cell cycle progression and EMSY is a BRCA2-associated repressor 
      protein. The aim was to investigate gene copy numbers of CCND1 and EMSY and to 
      determine if CCND1 amplification is associated with reduced survival of 
      tamoxifen-treated breast cancer patients. METHODS AND RESULTS: Fluorescence in 
      situ hybridization (FISH) was performed on 111 consecutive and 354 oestrogen 
      receptor (ER)+ tamoxifen-treated breast cancers. In the consecutive set, CCND1 
      and EMSY were amplified in 14.8% and 7.2%, respectively, and deleted in 8.7% and 
      13.5%, respectively. In the ER+ set, CCND1 and EMSY were amplified in 20.6% and 
      9.6%, respectively, and deleted in 1.7% and 4.2%, respectively. CCND1 and EMSY 
      gene amplifications were associated with decreased overall survival (OS) (P = 
      0.03 and P = 0.04, respectively) of patients in the ER+ set. CONCLUSION: As 
      hypothesized, CCND1 amplifications are associated with poor OS in ER+ patients. 
      EMSY amplification is also associated with poor OS. However, as >70% of EMSY 
      amplifications were CCND1 amplified, EMSY may not have any additional effect on 
      survival of ER+ breast cancer.
FAU - Kirkegaard, T
AU  - Kirkegaard T
AD  - Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, 
      Department of Surgery, Glasgow Royal Infirmary, Glasgow, UK.
FAU - Nielsen, K V
AU  - Nielsen KV
FAU - Jensen, L B
AU  - Jensen LB
FAU - Campbell, F M
AU  - Campbell FM
FAU - Muller, S
AU  - Muller S
FAU - Tovey, S M
AU  - Tovey SM
FAU - Brown, S
AU  - Brown S
FAU - Cooke, T G
AU  - Cooke TG
FAU - Bartlett, J M S
AU  - Bartlett JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080402
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Cyclin D)
RN  - 0 (Cyclins)
RN  - 0 (EMSY protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Repressor Proteins)
RN  - 094ZI81Y45 (Tamoxifen)
SB  - IM
MH  - Breast Neoplasms/drug therapy/*genetics
MH  - Cohort Studies
MH  - Cyclin D
MH  - Cyclins/*genetics
MH  - Female
MH  - Gene Dosage
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Proteins/*genetics
MH  - Nuclear Proteins/*genetics
MH  - Repressor Proteins/*genetics
MH  - Tamoxifen/pharmacology
EDAT- 2008/04/09 09:00
MHDA- 2008/07/09 09:00
CRDT- 2008/04/09 09:00
PHST- 2008/04/09 09:00 [pubmed]
PHST- 2008/07/09 09:00 [medline]
PHST- 2008/04/09 09:00 [entrez]
AID - HIS3007 [pii]
AID - 10.1111/j.1365-2559.2008.03007.x [doi]
PST - ppublish
SO  - Histopathology. 2008 May;52(6):698-705. doi: 10.1111/j.1365-2559.2008.03007.x. 
      Epub 2008 Apr 2.